Kitamura Hiroshi, Honma Ichiya, Torigoe Toshihiko, Hariu Hiroyuki, Asanuma Hiroko, Hirohashi Yoshihiko, Sato Eiji, Sato Noriyuki, Tsukamoto Taiji
Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Urology. 2007 Jul;70(1):38-42. doi: 10.1016/j.urology.2007.03.040.
To assess the expression of livin, a member of the inhibitor of apoptosis protein family, in renal cell carcinoma (RCC) and to determine its prognostic relevance.
Immunohistochemical staining for livin was performed using paraffin-embedded tissues from 45 cases of RCC. Then we assessed anti-livin antibodies (Abs) in patient sera by enzyme-linked immunosorbent assay and Western blotting. Disease-specific survival of patients was assessed, and differences between the immunohistologically livin-positive and livin-negative groups and between the anti-livin Ab-positive and anti-livin Ab-negative groups were compared with recurrence-free survival using the Kaplan-Meier method and log-rank test.
Of the 45 RCC specimens, 26 (57.8%) showed positive staining of livin immunohistochemically. In the RCC patients, anti-livin antibodies were detected and their levels were significantly higher than those in healthy volunteers. However, there was no difference in disease-specific survival between the livin-positive and livin-negative patients or between the anti-livin-positive and anti-livin-negative patients.
Although livin expression may not provide predictive information, it may be recognized as a tumor antigen by the immune system in RCC patients.
评估凋亡抑制蛋白家族成员Livin在肾细胞癌（RCC）中的表达，并确定其预后相关性。
使用45例RCC石蜡包埋组织进行Livin免疫组化染色。然后通过酶联免疫吸附测定和蛋白质印迹法评估患者血清中的抗Livin抗体（Abs）。评估患者的疾病特异性生存情况，并使用Kaplan-Meier法和对数秩检验比较免疫组化Livin阳性和阴性组以及抗Livin抗体阳性和阴性组之间无复发生存的差异。
在45例RCC标本中，26例（57.8%）免疫组化显示Livin染色阳性。在RCC患者中检测到抗Livin抗体，其水平显著高于健康志愿者。然而，Livin阳性和阴性患者之间或抗Livin阳性和阴性患者之间的疾病特异性生存没有差异。
虽然Livin表达可能无法提供预测信息，但它可能被RCC患者免疫系统识别为肿瘤抗原。
